Little Women with Big Voices Expose HPV Vaccine Dangers

Little Women with Big Voices Expose HPV Vaccine Dangers

Press Release
Immediate Release

Contact: Bobbie Cowan
Phone: 818.980.2372
Email: bobbicowan@sbcglobal.net

Website URL: http://truthaboutgardasil.org

Click On The Graphs Above For Full Size Viewing

March 8, 2010 – Called the “Little Women,” six women who have spent the past three years listening, documenting and researching parental concerns about Gardasil have been invited to formally present their information to the FDA on March 12. FDA participants include the Office of Communication, Outreach and Development/Center of Biologics (CBER), Office of Biostatistics and Epidemiology, and Office of Vaccines Research and Review.

The women making the presentation on behalf of the parents whose daughters have died or have been injured by the HPV vaccines are: Karen Maynor; mother of the late Megan Hild, New Mexico; Rosemary Mathis: whose daughter Lauren was adversely injured, North Carolina; Freda Birrell; political activist and lobbyist, Scotland and the United Kingdom; Leslie Carol Botha; broadcast journalist, Colorado; Cynthia Janak: research analyst, Illinois; and Janny Stokvis: research analyst, Netherlands.

Over 17,500 adverse reactions and 61 deaths have been reported to VAERS (estimated 1 to 10% of the population reporting). The National Vaccine Information Center (NVIC) has posted 272 VAERS reports of abnormal pap tests post-vaccination. Reports of deaths and injuries are now coming in from the United States, New Zealand, Australia, United Kingdom, France, Germany, Spain and India.

Birrell has compiled 40 pages of reports of deaths and injuries from the above countries for the FDA. Stokvis and Mathis have compiled data of vaccine injuries and deaths from VAERS. Botha is presenting studies on menstrual cycle evaluation to prevent vaccine injury – and the impact of aluminum on the endocrine system. Janak has researched vaccine ingredients and believes that she has found the reason as to why “healthy” girls have been injured or have died suddenly and unexpectedly within days weeks, months or potentially years after vaccination.

The group has prepared a power point presentation for the FDA “listening session.” Each participant will receive a file with over 236 pages of research, data and parental concerns. As soon as the Webinar is over, the group will be releasing their data and research to the public and to the media.

The group was dubbed “Little Women” by the FDA who is impressed with the women’s research and how quickly they mobilized a global movement of parents concerned about the safety and efficacy of the HPV vaccines. –End-

HPV VACCINES - CERVARIX AND GARDASIL

CERVARIX LOSS OF VISION - BLINDNESS

A

VAERS ID: 362372 Vaccination Date: 0000-00-00 Age: Onset Date: 0000-00-00 Days later: Gender: Female Submitted: 2009-10-22 State: Entered: 2009-10-22	Life Threatening Illness? No Died? No Disability? No Recovered? Yes ER or Doctor Visit? No Hospitalized? No Current Illness: Unknown Diagnostic Lab Data: UNK Previous Vaccinations: Other Medications: Preexisting Conditions: CDC 'Split Type': B0598594A
Vaccination Manufacturer Lot Dose Route Site HPV2 GLAXOSMITHKLINE BIOLOGICALS UN UN
Administered by: Other Purchased by: Other Symptoms: Blindness Write-up: This case was reported by a physician and described the occurrence of vision loss in a 15-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). On an unspecified date, the subject received unspecified dose of CERVARIX (unknown route, unknown lot number). In 2009, at an unspecified time after vaccination with CERVARIX, the subject experienced vision loss for one month. This case was assessed as medically serious by GSK. At the time of reporting the event was resolved. The physician considered the event was possibly related to vaccination with CERVARIX.

It appears that this is not part of the MHRA Statistics but please note that the physician considered her condition was possibly related to Cervarix

B

VAERS ID: 368695 Vaccination Date: 2009-09-23 Age: 15.0 Onset Date: 2009-09-23 Days later: 0 Gender: Female Submitted: 2009-11-19 State: Entered: 2009-11-19	Life Threatening Illness? No Died? No Disability? No Recovered? Yes ER or Doctor Visit? No Hospitalized? No Current Illness: Unknown Diagnostic Lab Data: Previous Vaccinations: Other Medications: Preexisting Conditions: CDC 'Split Type': B0603421A
Vaccination Manufacturer Lot Dose Route Site HPV2 GLAXOSMITHKLINE BIOLOGICALS AHPVA052BA IM AR
Administered by: Other Purchased by: Other Symptoms: Dizziness, Flushing, Hypoventilation, Peripheral coldness, Pulse abnormal, Pulse pressure decreased, Pupils unequal, Vision blurred Write-up: This case was reported by a foreign regulatory authority (# GB-MHRA-ADR 2051655) and described the occurrence of a thready pulse in a 15-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). On 23 September 2009, the subject received a single dose of CERVARIX (0.5 ml, intramuscular, batch number: AHPVA052BA). On 23 September 2009, at an unspecified time after vaccination with CERVARIX, the subject experienced a thready pulse, weak pulse, facial and neck flushing, blurred vision, erratic pupils, shallow breathing, dizziness and cold feeling of the fingers. The regulatory authority reported that the events were clinically significant (or requiring intervention). The subject was treated with 2 doses of ADRENALINE. On 23 September 2009, the events were resolved. Verbatim Text: Pulse thready and very weak, flushing of neck and face. Erratic pupils, blurred vision, shallow breathing and cold fingers, also dizzy. Given 2 doses of ADRENALINE.

It appears that this was an anaphylactic reaction to the vaccine and was reported to the MHRA

E

VAERS ID: 372256 Vaccination Date: 2009-03-27 Age: 17.0 Onset Date: 2009-07-01 Days later: 96 Gender: Female Submitted: 2009-12-08 State: Entered: 2009-12-08	Life Threatening Illness? No Died? No Disability? No Recovered? No ER or Doctor Visit? No Hospitalized? No Current Illness: Unknown Diagnostic Lab Data: Unk Previous Vaccinations: Other Medications: Preexisting Conditions: CDC 'Split Type': B0610147A
Vaccination Manufacturer Lot Dose Route Site HPV2 GLAXOSMITHKLINE BIOLOGICALS UN UN
Administered by: Other Purchased by: Other Symptoms: Eye disorder, Multiple sclerosis, Neurological symptom Write-up: This case was reported by a physician via a sales representative and described the occurrence of multiple sclerosis in a 17-year-old female subject who was vaccinated with CERVARIX (Glaxosmithkline). Previous and/or concurrent vaccination included CERVARIX; Glaxosmithkline given on 27 February 2009. On 27 March 2009 the subject received 2nd dose of CERVARIX (unknown). Between July and August 2009, approximately 4 months after vaccination with CERVARIX, the subject experienced neurological eye symptoms. Examinations were performed by a neurologist who diagnosed multiple sclerosis. On 23 October 2009 the subject received the 3rd dose of CERVARIX. This case was assessed as medically serious by GSK. At the time of reporting the outcome of the events was unspecified.

What has not been reported are the symptoms this young woman was having after receiving the first dose and second dose of Cervarix before the onset of the neurological eye symptoms. Can someone please explain to me why would anyone give her the third dose of Cervarix when she had been just diagnosed with multiple sclerosis?

G

VAERS ID: 376317 Vaccination Date: 2008-07-10 Age: 21.0 Onset Date: 2008-07-16 Days later: 6 Gender: Female Submitted: 2010-01-08 State: Entered: 2010-01-08	Life Threatening Illness? No Died? No Disability? Yes Recovered? No ER or Doctor Visit? No Hospitalized? Yes, 7 days Extended hospital stay? No Current Illness: Familial risk factor Diagnostic Lab Data: Albumin, 07Aug2008, 4170mg/dl; Albumin CSF, 07Aug2008, 12.3mg/dl; Alpha 1 globulin, 07Aug2008, 3.9%; Alpha 2 globulin, 07Aug2008, 8.2%; Beta globulin, 07Aug2008, 11.1%; Borrelia burgdorferi immunoglo, 07Aug2008, negative; Borrelia burgdorfe Previous Vaccinations: Other Medications: Preexisting Conditions: CDC 'Split Type': D0060193A
Vaccination Manufacturer Lot Dose Route Site HPV2 GLAXOSMITHKLINE BIOLOGICALS AHPVA008AD IM RA
Administered by: Other Purchased by: Other Symptoms: Abnormal sensation in eye, Albumin CSF normal, Alpha 1 globulin normal, Alpha 2 globulin normal, Beta globulin normal, Blindness unilateral, Blood albumin normal, Blood immunoglobulin A, Blood immunoglobulin G normal, Blood immunoglobulin M, Borrelia burgdorferi serology negative, C-reactive protein normal, CSF cell count normal, CSF glucose normal, CSF immunoglobulin increased, CSF lactate normal, CSF lymphocyte count normal, CSF monocyte count, CSF oligoclonal band present, CSF protein normal, CSF white blood cell count negative, Conduction disorder, Immunoglobulins normal, Migraine, Multiple sclerosis, Neurological examination abnormal, Nuclear magnetic resonance imaging abnormal, Ophthalmological examination normal, Optic neuritis, Protein total normal, Somatosensory evoked potentials, Visual acuity reduced, Visual acuity tests abnormal, Visual evoked potentials abnormal, Visual impairment Write-up: This case was reported by a physician via a foreign regulatory authority (# DE-PEI-PEI2008021049) and described the occurrence of optic nerve neuritis, left, in a 20-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Family anamnesis included HPV associated severe cervical intraepithelial neoplasia/epithelial dysplasia of the mother. Previous vaccinations included the first and second doses of CERVARIX (GlaxoSmithKline), given on 27 December 2007 and 18 February 2008. On 10 July 2008 the subject received the third dose of CERVARIX (0.5 ml, unknown). Approximately six days post vaccination with CERVARIX, on 16 July 2008 or 17 July 2008, the subject experienced migraine-like headache and feeling of pressure behind left eyeball. Ophthalmological examinations, performed on 28 July 2008, were normal. The subject was treated with unspecified migraine medication prescribed by the family physician. Approximately 26 days post vaccination with CERVARIX, on 05 August 2008, the subject experienced nearly complete unilateral vision loss left. The subject was diagnosed with suspected optic neuritis left by an ophthalmologist. Optic neuritis left was confirmed by neurological examinations. This case was assessed as medically serious by GSK criteria. MRT of the cervical spine and the thoracic spine showed an inflammatory focus in the thoracic vertebra 1. CSF examination showed 4 cells and was positive for oligoclonal bands. The subject was treated with cortisone. Follow-up MRT, performed on an unknown date in October 2008, was normal. At the time of reporting, on 13 November 2008, examinations to exclude multiple sclerosis was not completed. At the time of reporting the final outcome of the events was unspecified. Follow-up information including a hospital report was received on 06 February 2009 from the foreign regulatory authority. At the time of the events the subject had no infection. The subject owns at home a healthy cat. The subject works in an office.

It does not appear that this case is included in the MHRA statistics.

GARDASIL – LOSS OF VISION

A 16-Year-Old Girl With Bilateral Visual Loss and Left Hemiparesis Following an

Immunization Against Human Papilloma Virus

Journal of Child Neurology Vol. 25 Number 3, March 2010 321-327

Francis J. DiMario, Jr, MD, Mirna Hajjar, MD, and Thomas Ciesielski, MD

We report the course of a 16-year-old girl who presented with near complete visual loss associated with chiasmal neuritis and a biopsy proven tumefactive demyelinating lesion on magnetic resonance imaging (MRI) in association with a recent immunization against human papilloma virus.

This young girl’s symptoms appeared 10 days after vaccination with Gardasil

Authors’Comments

It is possible that human papilloma virus was the precipitant for the demyelinating event in the patient presented here. It is tempting to speculate whether there may be a specific immune mechanism initiated with human papilloma virus not yet identified, which resulted in not only acute demyelinating encephalomyelitis but also in an unusual clinical course that resulted in persistent visual loss.

http://truthaboutgardasil.org